Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT01230021
Other study ID # F13CD-3760
Secondary ID U1111-1116-25332
Status Completed
Phase Phase 3
First received October 27, 2010
Last updated September 3, 2014
Start date November 2010
Est. completion date January 2012

Study information

Verified date September 2014
Source Novo Nordisk A/S
Contact n/a
Is FDA regulated No
Health authority Israel: Ministry of HealthUnited Kingdom: Medicines and Healthcare Products Regulatory AgencyUnited States: Food and Drug Administration
Study type Interventional

Clinical Trial Summary

This trial is conducted in Europe and United States of America (USA). The aim of this clinical trial is to investigate the pharmacokinetics (at which rate the substance is distributed and eliminated from the body) and the safety profile of catridecacog (recombinant factor XIII (rFXIII)) in children with congenital FXIII A-subunit deficiency. Young children (1 to less than 6 years old) with congenital FXIII deficiency are evaluated.


Recruitment information / eligibility

Status Completed
Enrollment 6
Est. completion date January 2012
Est. primary completion date January 2012
Accepts healthy volunteers No
Gender Both
Age group 1 Year to 6 Years
Eligibility Inclusion Criteria:

- Signed Informed Consent by subject's parents or subject's legally acceptable representative before any trial related activities. Trial related activities are any procedures that would not have been performed during the normal management of the subject

- Age 1 to less than 6 years old at the time of enrolment

- Congenital FXIII subunit-A deficiency previously documented by genotyping or evaluated by genotyping through blood sampling at screening visit

- Body weight at least 10 kg

Exclusion Criteria:

- Known antibodies to FXIII

- Hereditary or acquired coagulation disorder other than FXIII A-subunit congenital deficiency

- Platelet count (thrombocytes) of less than 50 × 10^9/L (at screening visit)

- Previous history of autoimmune disorder involving autoantibodies e.g., systemic lupus erythematosus

- Previous history of arterial or venous thromboembolic events e.g., cerebrovascular accident or deep vein thrombosis

- Known or suspected allergy to trial product or related products

- Any surgical procedure in the 30 days prior to enrolment and any planned surgery during the trial period

- Any disease or condition which, judged by the Investigator, could imply a potential hazard to the subject or interfere with the trial participation or trial outcome including renal and/or liver dysfunction

Study Design

Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment


Intervention

Drug:
catridecacog
Intravenous injection of a single dose of recombinant factor XIII, 35 IU/kg bodyweight

Locations

Country Name City State
United States Novo Nordisk Clinical Trial Call Center Columbus Ohio
United States Novo Nordisk Clinical Trial Call Center Minneapolis Minnesota

Sponsors (1)

Lead Sponsor Collaborator
Novo Nordisk A/S

Countries where clinical trial is conducted

United States,  Israel,  United Kingdom, 

Outcome

Type Measure Description Time frame Safety issue
Primary Area Under the Concentration vs. Time Curve (AUC) A measure of the exposure. Blood samples for the PK assessment were drawn pre-dose and up to 30 days after dosing. The PK of FXIII in children was assessed after a single i.v. dose of rFXIII 35 IU/kg. At pre-dose, 30 minutes, 24 hours, 7, 14, 21 and 30 days after dosing No
Secondary Area Under the Concentration vs. Time Curve (AUC0-8) A measure of exposure. From day 0 to day 30 No
Secondary Maximum Plasma Concentration (Cmax) for FXIII Maximum plasma concentration of the drug reached. At pre-dose, 30 minutes, 24 hours, 7, 14, 21 and 30 days after dosing No
Secondary Terminal Half-life (t½) Time point when half of the maximum plasma concentration is reached. From day 0 to day 30 No
Secondary Mean Residence Time (MRT) The mean residence time (MRT) of a drug in the body and related functions are derived for drugs which are intravenously administered. From day 0 to day 30 No
Secondary Total Plasma Clearance (CL) The total plasma clearance is a measure of the elimination of a drug from the body. Drugs are excreted primarily by the kidneys into the urine. Clearance is calculated as 'CL=Dose / AUC0-30 days'). From day 0 to day 30 No
Secondary Volume of Distribution at Steady State (Vss) Volume of distribution at steady state (Vss) is the theoretical volume that the total amount of administered drug would have to occupy (if it were uniformly distributed), to provide the same concentration as it is in blood plasma at steady state. Steady state is achieved when all variables are constant in spite of ongoing processes. At steady state No
Secondary Percentage of Subjects With One or More Adverse Events (AEs) Recorded From day 0 to day 30 No
Secondary Percentage of Subjects With One or More Serious Adverse Events (SAEs) From day 0 to day 30 No
Secondary Percentage of Subjects With Development of Anti-rFXIII Antibodies, Including Inhibitors (Neutralising Antibodies Against Factor XIII) At screening and day 30 No
Secondary Coagulation Related Parameters - Fibrinogen Day 0 and at day 30 No
Secondary Coagulation Related Parameters - Activated Partial Thromboplastin Time (aPTT, Seconds) Day 0 and day 30 No
Secondary Coagulation Related Parameters - Prothrombin Time (PT) (Seconds) Day 0 and day 30 No
Secondary Clot Solubility Test (Evaluated as Normal/Abnormal) Blood samples for clot solubility drawn at each visit (1 hour before and after dose administration). A clot solubility assay was used to screen for FXIII deficiency. The assay is based on the ability of urea to dissolve fibrin clots that have not undergone FXIII-induced stabilization. Normal blood clots generally remain stable for 24 hours or more, while clots in which fibrin molecules have not been cross-linked are soluble within minutes. The outcome of the test is normal (FXIII present; a clot is observed in the test tube) or abnormal (FXIII absent or very low level; no clot in test tube). Day 0 and day 30 No
Secondary Vital Signs - Pulse Day 0 and day 30 No
Secondary Vital Signs - Blood Pressure (Systolic and Diastolic) Day 0 and day 30 No
Secondary Physical Examination (Evaluated as Normal/Abnormal) From day 0 to day 30 No
See also
  Status Clinical Trial Phase
Completed NCT00978380 - Safety of Monthly Recombinant Factor XIII Replacement Therapy in Subjects With Congenital Factor XIII Deficiency: An Extension to Trial F13CD-1725 Phase 3
Completed NCT02568202 - Bridging Hemophilia B Experiences, Results and Opportunities Into Solutions (B-HERO-S) N/A
Completed NCT01949792 - A Trial Investigating the Pharmacokinetics and Pharmacodynamics of rFVIIa in Patients With Haemophilia A or B With or Without Inhibitors Phase 1
Completed NCT01205724 - Safety and Pharmacokinetics of NNC 0129-0000-1003 in Subjects With Haemophilia A Phase 1
Completed NCT01562587 - Pharmacokinetics of Single Bolus Dose of NovoSeven® in Paediatric and Adult Patients With Haemophilia A or B in a Non- Bleeding State Phase 1
Completed NCT00108797 - Trial of NovoSeven® in Haemophilia - Joint Bleeds Phase 4
Completed NCT01493778 - Safety and Efficacy of Turoctocog Alfa in Prevention and Treatment of Bleeds in Previously Untreated Children With Haemophilia A Phase 3
Completed NCT02490787 - Trial Investigating Safety, Pharmacokinetics and Pharmacodynamics of Concizumab Administered Subcutaneously to Haemophilia A Subjects Phase 1
Completed NCT00951405 - Safety and Efficacy of 3 Different Doses of Long Acting Factor VII in Haemophilia A or B Patients With Inhibitors Phase 2
Completed NCT01876745 - A Study to Evaluate Safety and Efficacy of NovoSeven® in Patients With Glanzmann's Thrombasthenia in Japan N/A
Completed NCT02920398 - A Multi-centre, Comparative, Double Blind, Randomised Cross-over Trial Investigating Single Dose Pharmacokinetics and Safety of Turoctocog Alfa Pegol From the Pivotal Process and Turoctocog Alfa Pegol From the Commercial Process in Patients With Severe Haemophilia A Phase 1
Completed NCT00984126 - Safety and Efficacy of Turoctocog Alfa (N8) in Prevention and On-demand Treatment of Bleeding Episodes in Subjects With Haemophilia A: An Extension to Trials NN7008-3543, NN7008-3545, NN7008-3600, NN7008-3893 and NN7008-4015 Phase 3
Completed NCT01228669 - Safety of NNC 0172-0000-2021 in Healthy Male Subjects and Subjects With Haemophilia A or B Phase 1
Completed NCT01988532 - Impact of Pain on Functional Impairment and Quality of Life in Adults With Hemophilia N/A
Completed NCT01234545 - Observational Study Describing the Usual Clinical Practice Use of NovoSeven® in the Home Treatment of Joint Bleeds in Patients With Haemophilia A or B and Inhibitors N/A
Completed NCT01779921 - Treatment of Congenital Factor VII Deficiency N/A
Completed NCT01563471 - Safety and Tolerability of Intravenous Doses of Activated Recombinant Human Factor VII in Healthy Volunteers Phase 1
Completed NCT02941354 - Evaluating the Pharmacokinetics of NovoEight® (Turoctocog Alfa) in Relation to BMI in Subjects With Haemophilia A Phase 1
Completed NCT02241694 - To Quantify the Range of Main Psychosocial Factors Affecting Patients and Caregivers in Their Daily Lives N/A
Completed NCT01238367 - A Single Dose Trial of Recombinant Factor VIII (N8) in Japanese Subjects With Haemophilia A: An Extension to Trial NN7008-3543 Phase 1